The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data are sometimes published as a condensed summary for the few compounds that reach the market, but the majority of studies are never made public and are often difficult to access in an automated way, even sometimes within the owning company itself. It is evident from many academic and industrial examples, that useful data mining and model development requires large and representative data sets and careful curation of the collected data. In 2010, under the auspices of the Innovative Medicines Initiative, the eTOX project starte...
In silico methods are increasingly being used for assessing the chemical safety of substances, as a ...
A first analysis of a database of shared preclinical safety data donated by thirteen pharmaceutical ...
The application of read-across and in silico tools for regulatory decision making has been limited f...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical...
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical...
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical...
The proposed manuscript would start with a justification of the relevance of data sharing (1) for im...
After their incorporation into human risk assessment, reports on preclinical animal studies in most ...
Non-clinical safety assessment is often faced with the challenge of assessing candidate compounds wi...
A first analysis of a database of shared preclinical safety data for 1214 small molecule drugs and d...
In silico methods are increasingly being used for assessing the chemical safety of substances, as a ...
In silico methods are increasingly being used for assessing the chemical safety of substances, as a ...
A first analysis of a database of shared preclinical safety data donated by thirteen pharmaceutical ...
The application of read-across and in silico tools for regulatory decision making has been limited f...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug...
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical...
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical...
There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical...
The proposed manuscript would start with a justification of the relevance of data sharing (1) for im...
After their incorporation into human risk assessment, reports on preclinical animal studies in most ...
Non-clinical safety assessment is often faced with the challenge of assessing candidate compounds wi...
A first analysis of a database of shared preclinical safety data for 1214 small molecule drugs and d...
In silico methods are increasingly being used for assessing the chemical safety of substances, as a ...
In silico methods are increasingly being used for assessing the chemical safety of substances, as a ...
A first analysis of a database of shared preclinical safety data donated by thirteen pharmaceutical ...
The application of read-across and in silico tools for regulatory decision making has been limited f...